Bioidentical Hormone Replacement Therapy (BHRT)
Bioidentical hormone replacement therapy, often shortened to BHRT, is a term used for hormone therapy involving hormones that are chemically identical to hormones produced by the human body. The word “bioidentical” describes the hormone itself; it does not mean that the medication is necessarily compounded.
FDA-approved hormone therapy products can also contain hormones that are chemically identical to hormones naturally produced by the body. Compounded bioidentical hormone preparations are a separate category and are not FDA-approved. Understanding that distinction is important when comparing hormone-therapy options.
FDA-approved hormone therapy and compounded BHRT
FDA-approved hormone medications go through the FDA approval process for their labeled uses, including review of safety, effectiveness and product quality. Compounded medications do not go through that same FDA premarket approval process.
That does not mean compounding has no role in hormone care. A compounded preparation may be considered when a patient has a medical need that cannot be met by an available FDA-approved medication. Examples can include a clinically necessary strength, dosage form or formulation consideration that is not suitably addressed by an available approved product.
Compounded medication is also not the same as an FDA-approved generic drug. A generic drug is FDA-approved and must meet the applicable approval requirements; a compounded preparation is made under a different regulatory framework.
For patients comparing options, useful questions include:
- Is there an FDA-approved hormone product that meets the treatment need?
- What hormone, strength and dosage form is being prescribed?
- Why is a compounded preparation being considered instead of an available approved product?
- What information should the patient understand about how the prescribed product is used?
- What follow-up does the prescriber recommend after treatment begins?
BHRT in menopause care
BHRT is commonly discussed in the context of perimenopause and menopause, but treatment decisions should be based on the individual patient rather than on the label “bioidentical” alone.
Patients researching menopausal hormone therapy may encounter both FDA-approved products and compounded preparations. The appropriate choice depends on the treatment goal, the patient’s medical history, the prescribed hormone or hormones, the dosage form and whether an approved product can meet the patient’s needs.
Newberry Express Pharmacy’s hormone-focused content includes a broader Menopause & Hormone Therapy section, as well as information about estradiol and progesterone. Those pages can help patients understand the medication-specific questions that may arise when discussing hormone therapy with a prescriber.
Why compounding may enter the discussion
Compounding allows a pharmacist to prepare a medication differently when a prescription calls for a patient-specific formulation that is not appropriately met by an available manufactured product. In hormone therapy, that may involve a legitimate prescription need related to strength, dosage form or formulation.
Compounding should not be understood as automatically better, safer, more effective or more “natural” than FDA-approved hormone therapy. It is a different way of preparing medication for situations in which an individual patient’s medical needs may require it.
Newberry Express Pharmacy currently identifies BHRT and hormone care among its compounding service areas. The pharmacy’s role is to support the medication and compounding process in coordination with the patient and healthcare provider when a compounded prescription is appropriate.
For a broader explanation of how compounded medications differ from commercially manufactured drugs, see Compounding Pharmacy Services.
Prescription and prescriber involvement
Hormone therapy requires an appropriate prescription and clinical decision-making by the patient’s healthcare provider. The prescriber determines whether hormone therapy is appropriate and selects the medication, dose and treatment approach based on the patient’s needs.
A compounding pharmacy does not replace that evaluation. Its role is to prepare a prescribed compounded medication when appropriate and to help patients and prescribers with pharmacy-related questions about the formulation and use of the prescription.
Testing practices can vary according to the clinical situation and the prescriber’s approach. No single saliva, urine or blood-spot testing method should be presented as a routine requirement for all patients considering BHRT.
Questions to discuss before choosing a hormone preparation
Before starting or changing hormone therapy, patients may want to ask their prescriber or pharmacist:
- Is the prescribed hormone available in an FDA-approved product?
- If a compounded preparation is being considered, what patient-specific need is it intended to address?
- How should the prescribed dosage form be used?
- What are the expected benefits, important risks and follow-up considerations for the prescribed therapy?
- Are there differences between the compounded preparation and available FDA-approved alternatives that matter for this patient?
The goal is not to choose a treatment simply because it is described as “bioidentical” or “compounded.” The useful question is which prescribed option appropriately addresses the individual patient’s medical needs.